Advertisement

Interleukin-8-Induced Invasion Assay in Triple-Negative Breast Cancer Cells

  • Mohammad M. Uddin
  • Bijaya Gaire
  • Betsy Deza
  • Ivana VancurovaEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2108)

Abstract

The pro-inflammatory and pro-angiogenic chemokine interleukin-8 (IL-8, CXCL8) induces proliferation and invasion of solid tumor cells. In many types of solid cancer, including triple-negative breast cancer (TNBC), the IL-8 expression is induced by proteasome inhibition. In this chapter, we describe a protocol for the analysis of TNBC cell invasion induced by IL-8 in response to proteasome inhibition by bortezomib (BZ). Using this approach, we show that BZ increases the invasion ability of TNBC cells, and that the BZ-increased TNBC cell invasion is suppressed by IκB kinase (IKK) inhibition, which also decreases the IL-8 expression. The experimental protocol includes the cell invasion assay, microscopic evaluation of the invading cells, and quantitative analysis of the obtained images. This protocol should be applicable also for measurement of chemokine-induced tumor cell invasion in other types of cancer cells.

Key words

Bortezomib Cancer cell invasion Chemokines Interleukin-8 IκB kinase Proteasome inhibition Triple-negative breast cancer 

Notes

Acknowledgements

This work was supported by NIH grant CA202775 to I. Vancurova.

References

  1. 1.
    Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14:6735–6741CrossRefGoogle Scholar
  2. 2.
    Lazennec G, Richmond A (2010) Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16:133–144CrossRefGoogle Scholar
  3. 3.
    Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A et al (2003) IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 22:256–265CrossRefGoogle Scholar
  4. 4.
    Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, Chavey C et al (2004) Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene 23:6105–6114CrossRefGoogle Scholar
  5. 5.
    Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L et al (2011) A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 13:R97CrossRefGoogle Scholar
  6. 6.
    Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N et al (2013) Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res 73:3470–3480CrossRefGoogle Scholar
  7. 7.
    Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071–3076PubMedGoogle Scholar
  8. 8.
    Richardson PG, Mitsiades C, Hideshima T, Anderson KC (2005) Proteasome inhibition in the treatment of cancer. Cell Cycle 4:290–296CrossRefGoogle Scholar
  9. 9.
    Shah JJ, Orlowski RZ (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23:1964–1979CrossRefGoogle Scholar
  10. 10.
    Kuhn DJ, Orlowski RZ (2012) The immunoproteasome as a target in hematologic malignancies. Semin Hematol 49:258–262CrossRefGoogle Scholar
  11. 11.
    McConkey DJ, Zhu K (2008) Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 11:164–179CrossRefGoogle Scholar
  12. 12.
    Chen YJ, Yeh MH, Yu MC, Wei YL, Chen WS, Chen JY et al (2013) Lapatinib-induced NFκB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors. Breast Cancer Res 15:R108CrossRefGoogle Scholar
  13. 13.
    Petrocca F, Altschuler G, Tan SM, Mendillo ML, Yan H, Jerry DJ et al (2013) A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell 24:182–196CrossRefGoogle Scholar
  14. 14.
    Deshmukh RR, Kim S, Elghoul Y, Dou QP (2017) P-glycoprotein inhibition sensitizes human breast cancer cells to proteasome inhibitors. J Cell Biochem 118:1239–1248CrossRefGoogle Scholar
  15. 15.
    Vu HY, Juvekar A, Ghosh C, Ramaswami S, Le DH, Vancurova I (2008) Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IκBα. Arch Biochem Biophys 475:156–163CrossRefGoogle Scholar
  16. 16.
    Manna S, Singha B, Phyo SA, Gatla HR, Chang TP, Sanacora S et al (2013) Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα. J Immunol 191:2837–2846CrossRefGoogle Scholar
  17. 17.
    Singha B, Gatla HR, Manna S, Chang TP, Sanacora S, Poltoratsky V et al (2014) Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to IL-8 promoter, resulting in increased IL-8 production in ovarian cancer cells. J Biol Chem 289:2687–2700CrossRefGoogle Scholar
  18. 18.
    Uddin MM, Zou Y, Sharma T, Gatla HR, Vancurova I (2018) Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: opportunity for combination therapy. PLoS One 13(8):e0201858.  https://doi.org/10.1371/journal.pone.0201858CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Mohammad M. Uddin
    • 1
  • Bijaya Gaire
    • 1
  • Betsy Deza
    • 1
  • Ivana Vancurova
    • 1
    Email author
  1. 1.Department of Biological SciencesSt. John’s UniversityQueensUSA

Personalised recommendations